Canaccord Genuity Reiterates a 'Buy' on Amarin Corp (AMRN); Vascepa Approved, Focus Shifts to BD

July 27, 2012 2:44 PM EDT
Get Alerts AMRN Hot Sheet
Price: $3.02 --0%

Rating Summary:
    8 Buy, 11 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade AMRN Now!
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $27.00 (from $25.00).

Analyst, Ritu Baral, said, "Reiterate rating, increasing target to $27 on Vascepa approval & commercial, partnering potential. We now expect BD talks to intensify and Vascepa to receive NCE (5-year exclusivity). We have changed our valuation method from pure pNPV to a sum of the parts of a DCF of high triglyceride sales and pNPV of mixed dyslipidemia sales, which raises our target, on partial removal of regulatory risk."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $15.32 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Canaccord Genuity

Add Your Comment